BlossomHill Therapeutics, Inc. (BLSM) shareholders
Close on Nov 17, 2026Market cap $38.56MP/E –Yield –
Ownership
Who owns BlossomHill Therapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Chen Bihua Joint filing with Cormorant Asset Management, LP (11.79%) | 3,615,362 | 11.80% | 13D (active) | Aug 6, 2026 |
| OrbiMed Capital GP VIII LLC Joint filing with Orbimed Advisors LLC (8.90%) | 2,714,279 | 8.90% | 13D (active) | Aug 10, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (5.90%), Joseph Edelman (5.90%) | 1,808,533 | 5.90% | 13G (passive) | Aug 7, 2026 |
| Vivo Innovation Fund II Holdings, L.P. Joint filing with Vivo Innovation II, LLC (5.50%) | 1,681,240 | 5.50% | 13G (passive) | Aug 10, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jingrong Jean Cui | President and CEO, Director, 10% owner | 3,973,138 | 12.50% | Aug 10, 2026 |
| Yishan Li | Executive Chairman, Director, 10% owner | 3,859,703 | 12.14% | Aug 10, 2026 |
| Vincent Paul Liptak | General Counsel | 134,099 | 0.42% | Aug 10, 2026 |
| Jason A. Keyes | Chief Financial Officer | 700 | 0.00% | Aug 10, 2026 |
| Geoffrey Raymond Oxnard | Chief Medical Officer | 17,785 | 0.06% | Aug 10, 2026 |
| Advisors Llc Orbimed | Director | – | – | Aug 12, 2026 |
| Capital GP VIII LLC OrbiMed | Director | 2,714,279 | 8.54% | Aug 12, 2026 |
| Carl L. Gordon | Director | 2,714,279 | 8.54% | Aug 12, 2026 |
| John P. Schmid | Director | 6,000 | 0.02% | Aug 10, 2026 |
| Sundeep Agrawal | Director | 578,524 | 1.82% | Aug 10, 2026 |
| Bihua Chen | Director, 10% owner | – | – | Aug 10, 2026 |
| Sheila Gujrathi | Director | 90,160 | 0.28% | Aug 6, 2026 |
| Private Healthcare Fund III LP Cormorant | 10% owner | – | – | Aug 10, 2026 |
| Cormorant Asset Management, LP | 10% owner | – | – | Aug 10, 2026 |
| Cormorant Global Healthcare Master Fund, LP | 10% owner | – | – | Aug 10, 2026 |
| Private Healthcare Fund V. LP Cormorant | 10% owner | – | – | Aug 10, 2026 |
| Cormorant Private Healthcare Fund VI, LP | 10% owner | 3,301,534 | 10.39% | Aug 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Carl L. Gordon Director | Aug 10, 2026 | Buy | +625,000 | $16.00 | $10.00M | 2,714,279 |
| Carl L. Gordon Director | Aug 10, 2026 | Conversion | +1,039,996 | – | – | 1,039,996 |
| Carl L. Gordon Director | Aug 10, 2026 | Conversion | +1,049,283 | – | – | 2,089,279 |
| Capital GP VIII LLC OrbiMed Director | Aug 10, 2026 | Buy | +625,000 | $16.00 | $10.00M | 2,714,279 |
| Capital GP VIII LLC OrbiMed Director | Aug 10, 2026 | Conversion | +1,049,283 | – | – | 2,089,279 |
| Capital GP VIII LLC OrbiMed Director | Aug 10, 2026 | Conversion | +1,039,996 | – | – | 1,039,996 |
| John P. Schmid Director | Aug 10, 2026 | Buy | +6,000 | $16.00 | $96.00K | 6,000 |
| Yishan Li Executive Chairman, Director, 10% owner | Aug 10, 2026 | Conversion | +1,600,682 | – | – | 1,600,682 |
| Yishan Li Executive Chairman, Director, 10% owner | Aug 10, 2026 | Conversion | +124,779 | – | – | 124,779 |
| Yishan Li Executive Chairman, Director, 10% owner | Aug 10, 2026 | Conversion | +113,435 | – | – | 1,714,117 |
| Jason A. Keyes Chief Financial Officer | Aug 10, 2026 | Buy | +700 | $16.00 | $11.20K | 700 |
| Jingrong Jean Cui President and CEO, Director, 10% owner | Aug 10, 2026 | Conversion | +113,435 | – | – | 1,714,117 |
| Jingrong Jean Cui President and CEO, Director, 10% owner | Aug 10, 2026 | Conversion | +124,779 | – | – | 124,779 |
| Jingrong Jean Cui President and CEO, Director, 10% owner | Aug 10, 2026 | Conversion | +1,600,682 | – | – | 1,600,682 |
| Cormorant Private Healthcare Fund VI, LP 10% owner | Aug 10, 2026 | Conversion | +1,701,541 | – | – | 3,301,534 |
| Cormorant Private Healthcare Fund VI, LP 10% owner | Aug 10, 2026 | Conversion | +1,599,993 | – | – | 1,599,993 |
| Cormorant Private Healthcare Fund VI, LP 10% owner | Aug 10, 2026 | Buy | +312,500 | $16.00 | $5.00M | 3,614,034 |
| Sundeep Agrawal Director | Aug 10, 2026 | Conversion | +578,524 | – | – | 578,524 |
| Vincent Paul Liptak General Counsel | Aug 10, 2026 | Conversion | +22,687 | – | – | 22,687 |
| Vincent Paul Liptak General Counsel | Aug 10, 2026 | Buy | +2,200 | $16.00 | $35.20K | 111,412 |
| Vincent Paul Liptak General Counsel | Aug 7, 2026 | Buy | +2,500 | $15.80 | $39.50K | 109,212 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 3 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BlossomHill Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 51,898 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?